Experimental immune therapy takes aim at pancreatic cancer

NCT ID NCT03192462

Completed Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new experimental therapy using special immune cells (T cells) trained to attack proteins found on pancreatic cancer cells. The trial included 37 patients whose cancer had returned or not responded to standard treatment, or who chose not to have chemotherapy. The main goals were to check safety and whether patients could complete all six infusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: multiTAA specific T cells (immune cells targeting cancer proteins)
What this could lead to: If it works, this could point toward a new immune-based treatment for pancreatic cancer that targets multiple cancer-specific proteins.
What could go wrong: This is an early-phase trial (phase 1/2) with only 37 participants, so results may not apply broadly. The treatment is experimental and not FDA-approved; side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Baylor Clinic

Houston, Texas, 77030, United States
Harris Health System - Smith Clinic

Houston, Texas, 77054, United States
Houston Methodist Hospital

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.